Barrow Hanley Mewhinney & Strauss LLC Has $51.73 Million Stock Holdings in Smith & Nephew plc (NYSE:SNN)

Barrow Hanley Mewhinney & Strauss LLC reduced its holdings in Smith & Nephew plc (NYSE:SNN - Free Report) by 46.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,104,505 shares of the medical equipment provider's stock after selling 1,844,022 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned 0.48% of Smith & Nephew worth $51,729,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sei Investments Co. lifted its holdings in shares of Smith & Nephew by 229.8% during the fourth quarter. Sei Investments Co. now owns 75,215 shares of the medical equipment provider's stock valued at $1,849,000 after purchasing an additional 52,411 shares during the last quarter. American Century Companies Inc. lifted its stake in Smith & Nephew by 7.2% during the fourth quarter. American Century Companies Inc. now owns 136,438 shares of the medical equipment provider's stock valued at $3,354,000 after buying an additional 9,118 shares in the last quarter. Summit Global Investments acquired a new position in shares of Smith & Nephew in the fourth quarter worth about $433,000. Boston Partners increased its position in shares of Smith & Nephew by 13.1% in the fourth quarter. Boston Partners now owns 89,682 shares of the medical equipment provider's stock worth $2,204,000 after acquiring an additional 10,398 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Smith & Nephew by 4.3% during the fourth quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider's stock valued at $388,000 after acquiring an additional 653 shares during the period. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew Price Performance

Smith & Nephew stock remained flat at $28.13 during trading hours on Thursday. 922,351 shares of the company's stock traded hands, compared to its average volume of 778,289. Smith & Nephew plc has a 1 year low of $23.65 and a 1 year high of $31.72. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $12.30 billion, a price-to-earnings ratio of 13.02, a P/E/G ratio of 1.26 and a beta of 0.83. The company's fifty day moving average is $27.30 and its two-hundred day moving average is $26.89.

Smith & Nephew Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be issued a dividend of $0.447 per share. This represents a dividend yield of 2.5%. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. The ex-dividend date of this dividend is Friday, March 28th. Smith & Nephew's dividend payout ratio (DPR) is currently 41.20%.

Analyst Upgrades and Downgrades

SNN has been the subject of a number of recent analyst reports. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Canaccord Genuity Group reiterated a "hold" rating and set a $27.00 price target on shares of Smith & Nephew in a report on Monday, March 17th. Finally, UBS Group lowered Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $27.00.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.